Guidance on nitrosamine impurities in medications : evaluating and managing the risks of N-nitrosamine impurities in human pharmaceutical, biological and radiopharmaceutical products.: H164-327/2026E-1-PDF
"This guidance represents Health Canada's current thinking and recommendations on issues related to N-nitrosamine impurities (nitrosamine impurities or nitrosamines). This guidance may be subject to change as new information becomes available and if further guidance is needed for applicants and market authorization holders (MAHs)"--Background, page 1.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.966906&sl=0
| Department/Agency |
|
|---|---|
| Title | Guidance on nitrosamine impurities in medications : evaluating and managing the risks of N-nitrosamine impurities in human pharmaceutical, biological and radiopharmaceutical products. |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Format | Digital text |
| Electronic document | |
| Note(s) |
|
| Publishing information |
|
| Description | 1 online resource (iii, 64 pages) : illustrations |
| ISBN | 9781100010342 |
| Catalogue number |
|
| Edition |
|
| Subject terms |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.Page details
- Date modified: